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High blood pressure is of pandemic proportions with between 25-33% of the world's population 1 affected (Go et al., 2014) . Its asymptomatic characteristic and multiple potential causes make this 2 syndrome notoriously difficult to treat clinically. Interventions to control blood pressure are of high 3 importance, as sustained hypertension is a major risk factor for stroke, heart disease, atherosclerosis 4 and renal damage (Lewington et al., 2002 ). Here we compare interventional approaches for the 5 treatment of hypertension with our focus on a novel anti-hypertensive target. 6
Do we need new treatments for hypertension? 7
Despite the armoury of anti-hypertensive medications currently available, only around 50% of 8 treated patients have adequate blood pressure control (Go et al., 2014) , an alarming statistic given 9 that a 10mmHg rise in blood pressure doubles the risk of death from cardiovascular disease, and 10 each 2 mmHg rise in blood pressure increases the risk of stroke by 10% (Lewington et al., 2002) . 11
Several possible factors may underpin this failure to control blood pressure, including white coat 12 hypertension, sub-optimal treatment regimens and poor patient compliance. When other causes 13 are excluded, true multi-drug resistant hypertension has been estimated to account for ~10% of all 14 cases (de la Sierra et al., 2011; Persell, 2011) . Poor adherence to anti-hypertensive medication is 15 seen in a large proportion of patients -up to 40% of patients with newly diagnosed hypertension 16 choose to discontinue their medication within 12 months (Mazzaglia et al., 2005) , and 25% of 17 patients enrolled into specialist hypertension clinics were non-adherent to treatment (Tomaszewski 18 et al., 2014) . This is undoubtedly related to the relatively high rate of side effects, which affect over 19 one third of patients being treated for an otherwise largely asymptomatic condition (Benson et al., 20 2003) . In order to address patient compliance, intolerance and drug-resistance, there is a pressing 21 need for a wider range of treatment options to control blood pressure. 22
At present, pharmacological treatments for hypertension are dominated by drugs targeting the 23 renin-angiotensin aldosterone system, such as ACE-inhibitors, angiotensin receptor blockers, 24 diuretics and aldosterone antagonists targeting the mineralocorticoid receptor (Romero et al., 2015 ; 25 Roush et al., 2016) . In some countries, β-adrenoceptor blockers are prescribed to block 26 sympathetically mediated release of renin from the kidney (Wong et al., 2016) . Calcium channel 27 blockers and α1-adrenoceptor antagonists reduce vascular resistance (Cubeddu, 1988; Tocci et al., 28 2015) , while centrally-acting sympatholytic drugs such as the α2-adrenoceptor agonist clonidine and 29 the imidazoline receptor agonist moxondine, lower sympathetic activity (Sica, 2007) . The clinician 30 will typically follow a nationally-agreed protocol for drug type, dose and sequence/combinations 31 
Moving Forward 4
Given the multi-factorial nature of essential hypertension, it is hardly surprising that optimizing 5 patient treatment often requires an individualized, 'trial and error' approach, especially when our 6 ability to phenotype symptoms remains so limited. However, it is apparent that new and effective 7 interventional approaches are needed in some cases, to compliment current pharmacological 8 treatment options. It will become essential to better diagnose the blood pressure controlling 9 mechanisms in individuals in order to prescribe the most effective treatment strategy, whether 10 pharmacological and/or interventional. Preclinical animal and a small number of human studies 11 have confirmed the importance of the carotid bodies in mediating sympathetic overactivity and 12 hypertension, and have built a strong case to investigate therapeutic targeting of carotid bodies in 13 cardiovascular disease. To date, the only option to reduce carotid body activity long-term has been 14 the surgical removal of one or both carotid bodies, although an ablation catheter is currently being 15 trialled. While these procedures may have benefits in terms of guaranteeing patient compliance, 16 approaches which do not permanently disable carotid body function may be more desirable in the 17 long term. Thus, it may be attractive to also seek novel pharmacological compounds to selectively 18 inhibit aberrant carotid body afferent signalling, while sparing its ability to respond to physiological is performed first suggests an independent mechanism of action. in hypertensive rats and humans. Hypertension 62, 533-541. 7
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